IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer

被引：52

作者：

Emens, L. A. ^{[1
]}

Adams, S. ^{[2
]}

Barrios, C. H. ^{[3
]}

Dieras, V. C. ^{[4
]}

Iwata, H. ^{[5
]}

Loi, S. ^{[6
]}

Rugo, H. S. ^{[7
]}

Schneeweiss, A. ^{[8
]}

Winer, E. P. ^{[9
]}

Patel, S. ^{[10
]}

Henschel, V. ^{[11
]}

Swat, A. ^{[12
]}

Kaul, M. ^{[13
]}

Molinero, L. ^{[14
]}

Chui, S. Y. ^{[15
]}

Schmid, P. ^{[16
]}

机构：

[1] UPMC Hillman Canc Ctr, Dept Med Hematol Oncol, Pittsburgh, PA USA

[2] NYU, Langone Med Ctr, Sch Med, New York, NY USA

[3] Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Invest Ctr, Porto Alegre, RS, Brazil

[4] Ctr Eugene Marquis, Med Oncol, Rennes, France

[5] Aichi Canc Ctr Hosp, Breast Oncol, Nagoya, Aichi, Japan

[6] Peter MacCallum Canc Ctr, Div Res, Translat Breast Canc Genom Lab, Melbourne, Vic, Australia

[7] UCSF, Helen Diller Family Comprehens Canc Ctr, Breast Dept, San Francisco, CA USA

[8] Univ Hosp Heidelberg, German Canc Res Ctr, Heidelberg, Germany

[9] Dana Farber Canc Inst, Med, Boston, MA 02115 USA

[10] Genentech Inc, Med Oncol, San Francisco, CA USA

[11] Genentech Inc, Biostat, San Francisco, CA USA

[12] F Hoffmann La Roche, Clin Sci, Basel, Switzerland

[13] F Hoffmann La Roche, Canc Immunotherapy Clin Safety, Basel, Switzerland

[14] Genentech Inc, Oncol Biomarker Dev, San Francisco, CA 94080 USA

[15] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA

[16] Queen Mary Univ London, Barts Canc Inst, London, England

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.2244

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA16

引用

页码：S1148 / S1148

页数：1

共 50 条

[21] IMpassion130: Phase III trial comparing 1L atezolizumab with nab-paclitaxel versus placebo with nab-paclitaxel in treatment-naive patients with mTNBC
Emens, L.
Adams, S.
Loi, S.
Schneeweiss, A.
Rugo, H.
Winer, E.
Barrios, C.
Dieras, V.
de la Haba-Rodriguez, J.
Gianni, L.
Kusuma, N.
Chui, S. Y.
Schmid, P.
ANNALS OF ONCOLOGY, 2016, 27
[22] Atezolizumab plus nab-paclitaxel as first line therapy in Japanese patients with TNBC: A subgroup analysis of IMpassion130
Inoue, Kenichi
Shimomura, Akihiko
Kaneko, Koji
Ito, Yoshinori
Tsugawa, Koichiro
Yamauchi, Teruo
Tsurutani, Junji
Niikura, Naoki
Sawaki, Masataka
Doihara, Hiroyoshi
Miyoshi, Yasuo
Hasegawa, Ayumi
Nakagawa, Shintaro
Kuratomi, Hiroyasu
Iwata, Hiroji
ANNALS OF ONCOLOGY, 2019, 30
[23] Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer
Kang, Connie
Syed, Yahiya Y.
DRUGS, 2020, 80 (06) : 601 - 607
[24] Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer
Connie Kang
Yahiya Y. Syed
Drugs, 2020, 80 : 601 - 607
[25] Mechanisms of action and acquired resistance to atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer (mTNBC).
Molinero, Luciana
Emens, Leisha A.
Goldstein, Leonard D.
Abbas, Alexander R.
Koeppen, Hartmut
Rugo, Hope S.
Adams, Sylvia
Chui, Stephen Y.
Schmid, Peter
Loi, Sherene
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[26] IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab plus nab-paclitaxel in patients with treatment-naive, locally advanced or metastatic triple-negative breast cancer
Emens, L. A.
Loi, S.
Rugo, H. S.
Schneeweiss, A.
Dieras, V.
Iwata, H.
Barrios, C. H.
Nechaeva, M.
Molinero, L.
Duc, A. Nguyen
Funke, R.
Chui, S. Y.
Husain, A.
Winer, E. P.
Adams, S.
Schmid, P.
CANCER RESEARCH, 2019, 79 (04)
[27] Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 trial
Emens, L. A.
Molinero, L.
Adams, S.
Rugo, H. S.
Schneeweiss, A.
Dieras, V.
Iwata, H.
Barrios, C. H.
Nechaeva, M.
Winer, E. P.
Chang, C. W.
Chui, S. Y.
Schmid, P.
Loi, S.
ANNALS OF ONCOLOGY, 2020, 31 : S360 - S361
[28] Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Schmid, Peter
Rugo, Hope S.
Adams, Sylvia
Schneeweiss, Andreas
Barrios, Carlos H.
Iwata, Hiroji
Dieras, Veronique
Henschel, Volkmar
Molinero, Luciana
Chui, Stephen Y.
Maiya, Vidya
Husain, Amreen
Winer, Eric P.
Loi, Sherene
Emens, Leisha A.
LANCET ONCOLOGY, 2020, 21 (01): : 44 - 59
[29] Genomic profiling and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: An exploratory analysis from the phase 3 IMpassion130 trial
Emens, Leisha
Molinero, Luciana
Adams, Sylvia
Rugo, Hope S.
Schneeweiss, Andreas
Dieras, Veronique
Iwata, Hiroji
Barrios, Carlos
Winer, Eric P.
Chang, Ching-Wei
Chui, Stephen Y.
Schmid, Peter
Loi, Sherene
CANCER RESEARCH, 2021, 81 (04)
[30] Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
Jiang, Zefei
Ouyang, Quchang
Sun, Tao
Zhang, Qingyuan
Teng, Yuee
Cui, Jiuwei
Wang, Haibo
Yin, Yongmei
Wang, Xiaojia
Zhou, Xin
Wang, Yongsheng
Sun, Gang
Wang, Jingfen
Zhang, Lili
Yang, Jin
Qian, Jun
Yan, Min
Liu, Xinlan
Yi, Tienan
Cheng, Ying
Li, Man
Zang, Aimin
Wang, Shusen
Wang, Chuan
Wu, Xinhong
Cheng, Jing
Li, Hui
Lin, Ying
Geng, Cuizhi
Gu, Kangsheng
Xie, Chunwei
Xiong, Huihua
Wu, Xiaohong
Yang, Junlan
Li, Qingshan
Chen, Yiding
Li, Fanfan
Zhang, Anqin
Zhang, Yongqiang
Wu, Yudong
Nie, Jianyun
Liu, Qiang
Wang, Kun
Mo, Xueli
Chen, Lilin
Pan, Yueyin
Fu, Peifen
Zhang, Helong
Pang, Danmei
Sheng, Yuan
NATURE MEDICINE, 2024, 30 (02) : 249 - 256

← 1 2 3 4 5 →